These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18438661

  • 1. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    Koutsikos J, Leondi A.
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
    [No Abstract] [Full Text] [Related]

  • 2. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Palmedo H, Bender H, Schomburg A, Grünwald F, Schöneich G, Zamorra P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ.
    Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
    [Abstract] [Full Text] [Related]

  • 3. Re-186 HEDP treatment in breast cancer patients with bone metastases.
    Koutsikos J, Leondi A.
    J Natl Med Assoc; 2008 Apr; 100(4):447. PubMed ID: 18481487
    [No Abstract] [Full Text] [Related]

  • 4. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S.
    Adv Exp Med Biol; 1992 Apr; 324():115-29. PubMed ID: 1283494
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
    O'Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B, Coffey J, Cook G, Treleaven J, Horwich A, Huddart RA, Parker CC, Dearnaley DP.
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1055-61. PubMed ID: 16572306
    [Abstract] [Full Text] [Related]

  • 9. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Liepe K, Runge R, Kotzerke J.
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
    [Abstract] [Full Text] [Related]

  • 15. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer.
    Guerra UP, Englaro E, Cattaruzzi E.
    Tumori; 1997 Jan; 83(2):560-2. PubMed ID: 9226021
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
    Lam MG, Hoekstra A, de Klerk JM, van Rijk PP, Zonnenberg BA.
    Nuklearmedizin; 2009 Jan; 48(1):37-43. PubMed ID: 19212610
    [Abstract] [Full Text] [Related]

  • 19. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R.
    Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
    [Abstract] [Full Text] [Related]

  • 20. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
    Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL.
    Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.